134 related articles for article (PubMed ID: 29959150)
1. Pathology, Chemoprevention, and Preclinical Models for Target Validation in Barrett Esophagus.
Urbanska AM; Ponnazhagan S; Mozafari M
Cancer Res; 2018 Jul; 78(14):3747-3754. PubMed ID: 29959150
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
[TBL] [Abstract][Full Text] [Related]
3. Barrett esophagus: will effective treatment prevent the risk of progression to esophageal adenocarcinoma?
Sharma P
Am J Med; 2004 Sep; 117 Suppl 5A():79S-85S. PubMed ID: 15478857
[TBL] [Abstract][Full Text] [Related]
4. Barrett's esophagus-emerging concepts and controversies.
Schuchert MJ; Luketich JD
J Surg Oncol; 2007 Mar; 95(3):185-9. PubMed ID: 17323330
[No Abstract] [Full Text] [Related]
5. Antireflux surgery, barrett esophagus, and adenocarcinoma: there is still room for doubt.
Jamieson GG
Ann Surg; 2007 Jul; 246(1):22-3. PubMed ID: 17592285
[No Abstract] [Full Text] [Related]
6. Metformin use and the risk of esophageal cancer in Barrett esophagus.
Agrawal S; Patel P; Agrawal A; Makhijani N; Markert R; Deidrich W
South Med J; 2014 Dec; 107(12):774-9. PubMed ID: 25502158
[TBL] [Abstract][Full Text] [Related]
7. Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Morgan G
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):265. PubMed ID: 9521445
[No Abstract] [Full Text] [Related]
8. Chemoprevention in Barrett's esophagus: A pill a day?
Jankowski JA; Hooper PA
Gastrointest Endosc Clin N Am; 2011 Jan; 21(1):155-70. PubMed ID: 21112505
[TBL] [Abstract][Full Text] [Related]
9. Early Barrett's carcinoma of the esophagus.
Hölscher AH; Vallböhmer D; Bollschweiler E
Ann Thorac Cardiovasc Surg; 2008 Dec; 14(6):347-54. PubMed ID: 19131920
[No Abstract] [Full Text] [Related]
10. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease.
Greene CL; Worrell SG; DeMeester TR
Ann Surg; 2015 Dec; 262(6):910-24. PubMed ID: 25822684
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention in Barrett's Esophagus: Current Status.
Zeb MH; Baruah A; Kossak SK; Buttar NS
Gastroenterol Clin North Am; 2015 Jun; 44(2):391-413. PubMed ID: 26021201
[TBL] [Abstract][Full Text] [Related]
12. The effect of antireflux surgery on esophageal carcinogenesis in patients with barrett esophagus: a systematic review.
Chang EY; Morris CD; Seltman AK; O'Rourke RW; Chan BK; Hunter JG; Jobe BA
Ann Surg; 2007 Jul; 246(1):11-21. PubMed ID: 17592284
[TBL] [Abstract][Full Text] [Related]
13. Management of cancer risk in Barrett's esophagus.
Tan A; Macrae F
J Gastroenterol Hepatol; 2011 Oct; 26(10):1485-92. PubMed ID: 21592226
[TBL] [Abstract][Full Text] [Related]
14. Barrett's esophagus: so what!
van Blankenstein M
Dis Esophagus; 2002; 15(1):1-4. PubMed ID: 12060035
[No Abstract] [Full Text] [Related]
15. Endoluminal therapy for esophageal disease: an introduction.
Wolfsen HC
Gastrointest Endosc Clin N Am; 2010 Jan; 20(1):1-10, v. PubMed ID: 19951790
[TBL] [Abstract][Full Text] [Related]
16. The natural history of dysplasia and cancer in esophagitis and Barrett esophagus.
Spechler SJ
J Clin Gastroenterol; 2003; 36(5 Suppl):S2-5; discussion S26-8. PubMed ID: 12702959
[TBL] [Abstract][Full Text] [Related]
17. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma.
Oberg S; Wenner J; Johansson J; Walther B; Willén R
Ann Surg; 2005 Jul; 242(1):49-54. PubMed ID: 15973101
[TBL] [Abstract][Full Text] [Related]
18. Long-term endoscopic surveillance of Barrett's esophagus.
Sampliner RE
Am J Gastroenterol; 2003 Sep; 98(9):1912-3. PubMed ID: 14499764
[No Abstract] [Full Text] [Related]
19. Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Hur C; Broughton DE; Ozanne E; Yachimski P; Nishioka NS; Gazelle GS
Am J Gastroenterol; 2008 Oct; 103(10):2432-42. PubMed ID: 18775019
[TBL] [Abstract][Full Text] [Related]
20. HLA-DR expression in tumor epithelium is an independent prognostic indicator in esophageal adenocarcinoma patients.
Dunne MR; Michielsen AJ; O'Sullivan KE; Cathcart MC; Feighery R; Doyle B; Watson JA; O'Farrell NJ; Ravi N; Kay E; Reynolds JV; Ryan EJ; O'Sullivan J
Cancer Immunol Immunother; 2017 Jul; 66(7):841-850. PubMed ID: 28315927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
